S
MRNA icon

Surevest’s Moderna MRNA Stock Holding History

Surevest’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10
Closed -$1K – 561
2022
Q2 		$1K Buy
+10
New +$1.43K ﹤0.01% 509

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Surevest's MRNA Position: Q3 2022 in Review

Surevest sold out of Moderna (MRNA) in Q3 2022, closing a stake of 10 shares — an estimated $1K sold.

Surevest first reported a position in MRNA in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Surevest reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
  • Surevest sold 10 Moderna shares in Q3 2022, an estimated $1K.
  • Surevest first reported a position in Moderna in Q2 2022 and held it in 1 quarter.
  • Surevest's Moderna position peaked at $1K in Q2 2022.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Surevest's 13F filing for Q3 2022, filed 14 Nov 2022.